Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 11:12 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1369–1392 of 13,937 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Trial Clear all

Conditions: Non-melanoma Skin Cancer
Interventions: Solaraze and Vaniqa; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 2
States / cities: Birmingham, Alabama

Conditions: Depressive Disorder, Depression, Depression, Postpartum, Behavioral Symptoms, Mood Disorders, Mental Disorder, Pregnancy Complications, Postpartum Blues, PPD, Postpartum Disorder
Interventions: Ganaxolone, Placebo; Drug
Lead sponsor: Marinus Pharmaceuticals; Industry
Eligibility: 18 Years to 48 Years · Female only
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 33
States / cities: Glendale, California • Lemon Grove, California • Long Beach, California + 29 more

Conditions: COPD
Interventions: Zofin, Placebo; Drug · Other
Lead sponsor: ZEO ScientifiX, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Intravenous Administration
Interventions: Buzzy Bee, Vapocoolent, Placebo; Device · Drug · Other
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 6 Years to 18 Years
Enrollment: 172 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: PTSD
Interventions: Glecaprevir/pibrentasvir, Placebo; Drug · Other
Lead sponsor: White River Junction Veterans Affairs Medical Center; Federal
Eligibility: 19 Years to 70 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: White River Junction, Vermont

Conditions: Autism Spectrum Disorder
Interventions: Behavior therapy, Psychoeducation; Behavioral · Other
Lead sponsor: Stanford University; Other
Eligibility: 2 Years to 7 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Stanford, California • Alamogordo, New Mexico

Conditions: Hypothalamic Obesity, Multiple Pituitary Hormone Deficiency Genetic Form, Septo-Optic Dysplasia, Optic Nerve Hypoplasia, Childhood-onset Combined Pituitary Hormone Deficiency, Pituitary Stalk Interruption Syndrome
Interventions: Setmelanotide, Placebo; Drug
Lead sponsor: Rhythm Pharmaceuticals, Inc.; Industry
Eligibility: 4 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 8
States / cities: Birmingham, Alabama • Aurora, Colorado • Chicago, Illinois + 5 more

Conditions: MPS-IH (Hurler Syndrome)
Interventions: Experimental: OTL-203, Active Comparator: Allo-HSCT; Genetic
Lead sponsor: Orchard Therapeutics; Industry
Eligibility: 28 Days to 30 Months
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Female Dyspareunia
Interventions: Low intensity shockwave treatment to pelvic floor region plus typical physical therapy, Sham shockwave treatment plus typical physical therapy; Device
Lead sponsor: SoftWave Tissue Regeneration Technologies; Industry
Eligibility: 21 Years to 65 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Wauwatosa, Wisconsin

Conditions: Breast Reconstruction, Breast Cancer
Interventions: Opioid Educational Video; Behavioral
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older · Female only
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Contraception
Interventions: LF111 (drospirenone); Drug
Lead sponsor: Laboratories Leon Farma, S.A.; Industry
Eligibility: 15 Years and older · Female only
Enrollment: 1,552 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 37
States / cities: Birmingham, Alabama • Anaheim, California • Costa Mesa, California + 32 more

Conditions: Rib Fracture, Rib Fracture Multiple
Interventions: Cryoneurolysis, Local anesthetic peripheral nerve block, Sham Cryoneurolysis, Sham peripheral nerve block; Device · Procedure
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 5
States / cities: La Jolla, California • Bethesda, Maryland • Boston, Massachusetts + 1 more

Conditions: Prostate Cancer
Interventions: Curcumin, Placebo; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 40 Years to 89 Years · Male only
Enrollment: 291 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: THA
Interventions: Duloxetine, Placebo; Drug · Other
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Liver Diseases, Healthy
Interventions: Zongertinib; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Beliefs
Interventions: Corrective message framing and humor; Behavioral
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 21 Years to 99 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Muscle Invasive Bladder Cancer
Interventions: Radiation and chemoradiation, Radical cystectomy; Radiation · Procedure
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 89 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Advanced Breast Cancer, Advanced Prostate Cancer, Advanced Lung Cancer, Advanced Colorectal Carcinoma, Advanced Colorectal Adenocarcinoma
Interventions: ENGAGE, Supportive Care; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Anxiety
Interventions: attention bias modification for anxiety; Behavioral
Lead sponsor: Hunter College of City University of New York; Other
Eligibility: 18 Years to 40 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Psoriasis
Interventions: CP-690,550, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 197 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 29
States / cities: Tucson, Arizona • Little Rock, Arkansas • Oceanside, California + 23 more

Conditions: Shoulder Surgery, Obesity
Interventions: Ultrasound-Guided Interscalene Brachial Plexus Block, Phrenic-Sparing Block Combination (Experimental), Bupivacaine HCl 0.5% Injectable Solution, Dexamethasone 4mg; Procedure · Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Opiate Addiction
Interventions: Methadone, Buprenorphine/naloxone; Drug
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 2
States / cities: Buffalo, New York

Conditions: Gestational Diabetes Mellitus, Pregnancy, High Risk
Interventions: Metformin, Insulin; Drug
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1,572 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 26
States / cities: Tuscaloosa, Alabama • Los Angeles, California • San Francisco, California + 20 more

Conditions: Lipid Disorder, Triglycerides High, Dyslipidemias
Interventions: Icosapent Ethyl 1000 MG [Vascepa]; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 21 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

Topical Diclofenac and Topical DFMO Chemoprevention Trial in Subjects With a History of Skin Cancer

A Clinical Trial of Oral Ganaxolone in Women With Postpartum Depression

Zofin to Treat Chronic Obstructive Pulmonary Disease (COPD)

Clinical Trial Testing Buzzy Bee vs Vapocoolant During IV Placement

Glecaprevir/Pibrentasvir for Post-traumatic Stress Disorder

Telehealth-Enabled Versus In-Person Parent-Mediated Behavioral Treatment for Challenging Behaviors in Children With ASD

A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)

A Study to Investigate the Efficacy and Safety of OTL-203 in Subjects With MPS-IH Compared With Standard of Care With Allogeneic HSCT

A Study of Participants Ages 21-65 Diagnosed With Dyspareunia and the Effects of Low Intensity Shockwave Treatment

SAVE Trial: SAfe Opioid Use Video Education

Safety, Efficacy, Tolerability and Pharmacokinetics of LF111 (Drospirenone 4.0 mg) During 13 Cycles

Ultrasound-Guided Percutaneous Cryoneurolysis to Treat Pain Following Thoracic Trauma

Trial of Curcumin to Prevent Progression of Low-risk Prostate Cancer Under Active Surveillance

Duloxetine for Perioperative Pain in Hip Arthroplasty: A RCT

A Study to Test How Zongertinib is Taken up in the Blood of People With and Without Liver Problems

Does Framing and Humor Improve the Effectiveness of Messages About COVID-19 Vaccine

Radical Cystectomy Compared With Chemoradiation for Muscle Invasive Bladder Cancer

Engage Psychosocial Intervention for Cancer Symptoms

Attention Bias Modification for Anxiety: A Randomized Control Trial With Biomarkers

Effectiveness and Safety of 3 Dosing Regimens of CP-690,550 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Interscalene vs Phrenic-sparing Blocks in Obesity and Effect of Maximum Inspiratory Pressure

Buprenorphine and Methadone for Opioid Dependent Chronic Pain Patients

DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes

Vascepa to Accelerate Lipoprotein Uptake and Elimination